

# Liam R Brunham

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4160806/liam-r-brunham-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86  
papers

4,032  
citations

34  
h-index

63  
g-index

99  
ext. papers

4,944  
ext. citations

7.9  
avg, IF

5.57  
L-index

#	Paper	IF	Citations
86	The design and rationale of the Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypercholesterolemia (ACCURATE) study. <i>American Heart Journal Plus</i> , <b>2022</b> , 13, 100097		
85	Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia. <i>Atherosclerosis</i> , <b>2022</b> , 340, 35-43	3.1	2
84	The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification. <i>Genetics in Medicine</i> , <b>2021</b> ,	8.1	6
83	Influence of the LDL-receptor genotype on statin response in heterozygous familial hypercholesterolemia: insights from the Canadian FH Registry. <i>Canadian Journal of Cardiology</i> , <b>2021</b> ,	3.8	1
82	Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance. <i>Current Opinion in Lipidology</i> , <b>2021</b> , 32, 103-111	4.4	3
81	Regulated cell death pathways in doxorubicin-induced cardiotoxicity. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 339	9.8	56
80	Patient Perspectives Regarding Genetic Testing for Familial Hypercholesterolemia. <i>CJC Open</i> , <b>2021</b> , 3, 557-564	2	2
79	Sex Differences in the Presentation, Treatment, and Outcome of Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019286	6	1
78	The Interplay Between Titin, Polygenic Risk, and Modifiable Cardiovascular Risk Factors in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 848-856	3.8	3
77	Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. <i>Circulation</i> , <b>2021</b> , 143, 921-934	16.7	20
76	Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 1733-1742	3.8	1
75	Response by Brunham et al to Letter Regarding Article, "Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis". <i>Circulation</i> , <b>2021</b> , 144, e122	16.7	0
74	The effects of cholesterol accumulation on Achilles tendon biomechanics: A cross-sectional study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257269	3.7	1
73	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , <b>2021</b> , 398, 1713-1725	4.0	14
72	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2021</b> , 41, 2632-2640	9.4	6
71	Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2682-2693	15.1	24
70	Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes. <i>Scientific Reports</i> , <b>2020</b> , 10, 10363	4.9	16

69	Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 390-399	16.2	71
68	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach-Reply. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1453	16.2	
67	Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2020</b> , 40, 267-278	9.4	37
66	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 217-229	16.2	85
65	Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation. <i>American Journal of Preventive Cardiology</i> , <b>2020</b> , 2, 100036	1.9	1
64	Chromosome 1q21.2 and additional loci influence risk of spontaneous coronary artery dissection and myocardial infarction. <i>Nature Communications</i> , <b>2020</b> , 11, 4432	17.4	22
63	Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia. <i>Circulation Genomic and Precision Medicine</i> , <b>2020</b> , 13, 515-523 <sup>5.2</sup>		13
62	HDL and pancreatic βcells: a SMO-king gun?. <i>Journal of Lipid Research</i> , <b>2020</b> , 61, 468-469	6.3	1
61	Priorities for Services in Young Patients With Atherosclerotic Cardiovascular Disease and Their Family Members: An Exploratory Mixed-Methods Study. <i>CJC Open</i> , <b>2019</b> , 1, 107-114	2	1
60	Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes. <i>Stem Cell Reports</i> , <b>2019</b> , 12, 996-1006	8	30
59	Premature Atherosclerotic Cardiovascular Disease: Trends in Incidence, Risk Factors, and Sex-Related Differences, 2000 to 2016. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e012178	6	30
58	Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 512-522	15.1	67
57	Estimating the Prevalence of Familial Hypercholesterolemia in Acute Coronary Syndrome: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 1322-1331	3.8	20
56	Molecular regulation of plasma lipid levels during systemic inflammation and sepsis. <i>Current Opinion in Lipidology</i> , <b>2019</b> , 30, 108-116	4.4	13
55	Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 854-862	10.2	44
54	Diagnostic accuracy of ultrasound and MRI for Achilles tendon xanthoma in people with familial hypercholesterolemia: A systematic review. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 40-48	4.9	9
53	Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 401-410	3.5	5
52	Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. <i>Head and Neck</i> , <b>2018</b> , 40, 1425-1433	4.2	2

51	Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1004-1009	3.8	16
50	The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 888-895	3.3	8
49	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 355-362	5.5	32
48	Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. <i>Cardiovascular Research</i> , <b>2018</b> , 114, 1073-1081	9.9	29
47	Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 116-121	4.9	16
46	CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis. <i>Scientific Reports</i> , <b>2018</b> , 8, 16764	4.9	18
45	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1553-1563	3.8	58
44	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. <i>Atherosclerosis</i> , <b>2018</b> , 277, 419-424	3.1	10
43	Simplified Canadian Definition for Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1210-1214	3.8	36
42	CRISPR/Cas9-mediated genome editing in human stem cell-derived cardiomyocytes: Applications for cardiovascular disease modelling and cardiotoxicity screening. <i>Drug Discovery Today: Technologies</i> , <b>2018</b> , 28, 13-21	7.1	12
41	Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1558-1562	13.4	29
40	Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 891-910	2.6	12
39	Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. <i>Journal of Critical Care</i> , <b>2017</b> , 38, 289-294	4	68
38	Use of Human Pluripotent Stem Cell Derived-Cardiomyocytes to Study Drug-Induced Cardiotoxicity. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]</i> , <b>2017</b> , 73, 22.5.1-22.5.22 <sup>2</sup>		
37	Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 385-392	3.8	17
36	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1290-1301	15.1	133
35	Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186200	3.7	26
34	Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 1636-1646	3.8	44

33	HDL as a Causal Factor in Atherosclerosis: Insights from Human Genetics. <i>Current Atherosclerosis Reports</i> , <b>2016</b> , 18, 71	6	7
32	Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. <i>Scientific Reports</i> , <b>2016</b> , 6, 25333	4.9	90
31	Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 28-39	1.9	14
30	A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 1079-84	36.3	155
29	Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1161-78	2.6	20
28	Targeted next-generation sequencing to diagnose disorders of HDL cholesterol. <i>Journal of Lipid Research</i> , <b>2015</b> , 56, 1993-2001	6.3	24
27	Comment on Rickels et al. Loss-of-Function Mutations in ABCA1 and Enhanced $\beta$ Cell Secretory Capacity in Young Adults. <i>Diabetes</i> 2015;64:193-199. <i>Diabetes</i> , <b>2015</b> , 64, e25-6; discussion e27	0.9	2
26	Human genetics of HDL: Insight into particle metabolism and function. <i>Progress in Lipid Research</i> , <b>2015</b> , 58, 14-25	14.3	35
25	Hunting human disease genes: lessons from the past, challenges for the future. <i>Human Genetics</i> , <b>2013</b> , 132, 603-17	6.3	30
24	Predicting Anthracycline-induced Cardiotoxicity in Children [Genome-Wide Association Study]. <i>FASEB Journal</i> , <b>2013</b> , 27, 663.3	0.9	
23	Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired $\beta$ cell function. <i>Diabetes</i> , <b>2012</b> , 61, 659-64	0.9	85
22	Medicine. Whole-genome sequencing: the new standard of care?. <i>Science</i> , <b>2012</b> , 336, 1112-3	33.3	58
21	Personalized Medicine: Temper Expectations--Response. <i>Science</i> , <b>2012</b> , 337, 911-911	33.3	2
20	Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. <i>Diabetes</i> , <b>2011</b> , 60, 3186-96	0.9	76
19	The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. <i>Thyroid</i> , <b>2010</b> , 20, 681-7	6.2	49
18	Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. <i>Diabetes Care</i> , <b>2010</b> , 33, 869-74	14.6	98
17	HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. <i>Current Opinion in Lipidology</i> , <b>2010</b> , 21, 178-85	4.4	98
16	Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. <i>Current Diabetes Reports</i> , <b>2010</b> , 10, 55-60	5.6	46

15	Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 548-54	9.4	85
14	Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 3579-89	6.6	105
13	Cholesterol in islet dysfunction and type 2 diabetes. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 403-8	15.9	105
12	Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. <i>Nature Medicine</i> , <b>2007</b> , 13, 340-7	50.5	315
11	Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. <i>Circulation Research</i> , <b>2006</b> , 99, 389-97	15.7	88
10	Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. <i>Circulation Research</i> , <b>2006</b> , 99, 672-4	15.7	98
9	Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. <i>Circulation</i> , <b>2006</b> , 114, 1301-9	16.7	70
8	Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. <i>Annual Review of Nutrition</i> , <b>2006</b> , 26, 105-29	9.9	127
7	Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 1052-62	15.9	389
6	Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 1333-42	15.9	190
5	Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene. <i>PLoS Genetics</i> , <b>2005</b> , 1, e83	6	107
4	Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. <i>Journal of Lipid Research</i> , <b>2003</b> , 44, 1470-80	6.3	74
3	Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 1322-32	9.4	212
2	Discoveries in sphingolipid metabolism, spinocerebellar ataxia and autoimmune disease. <i>Clinical Genetics</i> , <b>2003</b> , 64, 1-3	4	
1	Clarity is essential when using nucleotide number systems. <i>Atherosclerosis</i> , <b>2003</b> , 170, 349	3.1	